Ke Xiang Zhou
Director/Board Member presso BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Profilo
Ke Xiang Zhou is a Non-Executive Director at Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a Director at Xiamen LP Pharmaceutical Co., Ltd., and the General Manager & Director-Equity Investment at Cmbi Capital Management Shenzhen Co. Ltd.
He was previously a Non-Executive Director at Apollomics, Inc. (United States) and a Member-Supervisory Board at Shenzhen Chipscreen Biosciences Co., Ltd.
He also served as a Director at Eucure Beijing Biopharma Co Ltd from 2018 to 2021.
Dr. Zhou received his undergraduate degree from Southern Medical University and his doctorate from Peking University Health Science Center in 1990 and 1993.
Posizioni attive di Ke Xiang Zhou
| Società | Posizione | Inizio |
|---|---|---|
| BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. | Director/Board Member | 12/03/2018 |
| Cmbi Capital Management Shenzhen Co. Ltd. | Chief Executive Officer | 01/12/2015 |
Xiamen LP Pharmaceutical Co., Ltd.
 Xiamen LP Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Xiamen LP Pharmaceutical Co., Ltd. engages in the development of improved new drugs. It provides perfluoropropane human albumin microspheres for injection, pramipexole hydrochloride sustained-release tablets, and clonidine hydrochloride sustained-release tablets. The company was founded by Ying Ye and Cheng Ye on November 2, 2012 and is headquartered in Xiamen, China. | Director/Board Member | 01/01/2018 |
Precedenti posizioni note di Ke Xiang Zhou
| Società | Posizione | Fine |
|---|---|---|
| Eucure Beijing Biopharma Co Ltd | Director/Board Member | 01/08/2021 |
Apollomics, Inc. (United States)
 Apollomics, Inc. (United States) BiotechnologyHealth Technology Apollomics, Inc. operates as a sciences oncology company. It is a biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company was founded by Sanjeev Gurunath Redkar and Guo-Liang Yu on May 21, 2015 and is headquartered in Foster City, CA. | Director/Board Member | - |
| SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. | Director/Board Member | - |
Formazione di Ke Xiang Zhou
| Southern Medical University | Undergraduate Degree |
| Peking University Health Science Center | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. | Health Technology |
| BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. | Commercial Services |
| Aziende private | 4 |
|---|---|
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Apollomics, Inc. operates as a sciences oncology company. It is a biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company was founded by Sanjeev Gurunath Redkar and Guo-Liang Yu on May 21, 2015 and is headquartered in Foster City, CA. | Health Technology |
Xiamen LP Pharmaceutical Co., Ltd.
Xiamen LP Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Xiamen LP Pharmaceutical Co., Ltd. engages in the development of improved new drugs. It provides perfluoropropane human albumin microspheres for injection, pramipexole hydrochloride sustained-release tablets, and clonidine hydrochloride sustained-release tablets. The company was founded by Ying Ye and Cheng Ye on November 2, 2012 and is headquartered in Xiamen, China. | Commercial Services |
| Cmbi Capital Management Shenzhen Co. Ltd. | |
| Eucure Beijing Biopharma Co Ltd |
- Borsa valori
- Insiders
- Ke Xiang Zhou
